DUG DISCOVERY CASE HISTORY

An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future

Marco Tuccori\textsuperscript{ab}, Irma Convertino\textsuperscript{b}, Sara Ferraro\textsuperscript{b}, Giulia Valdiserra \textsuperscript{c}, Emiliano Cappello \textsuperscript{c}b, Elisabetta Fini\textsuperscript{b} and Daniele Focosi\textsuperscript{d}

\textsuperscript{a}Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, Unit of Adverse Drug Reactions Monitoring, Pisa, Italy; \textsuperscript{b}Department of Clinical and Experimental Medicine, Unit of Pharmacology and Pharmacovigilance, University of Pisa, Pisa, Italy; \textsuperscript{c}North Western Tuscany Blood Bank, University Hospital of Pisa, Pisa, Italy

ABSTRACT

Introduction: In the COVID-19 pandemic emergency, research has been oriented toward the development of therapies that could cure critically ill patients and treatments that can reduce the number of hospitalized patients, in order to ease the pressure on health-care systems. Bamlanivimab, developed from human convalescent plasma, was the first monoclonal antibody to become available for emergency use in several countries. Expectations related to its use in COVID-19 patients as a single agent have been largely disregarded, especially against E484K-carrying SARS-CoV-2 variants.

Areas covered: In this drug discovery case history, the development of the drug is described starting from the identification and selection of the antibody, from the pre-clinical and clinical trials up to the post-authorization phase.

Expert opinion: Bamlanivimab has shown some efficacy in patients with mild to moderate COVID-19. Initially approved as a monotherapy, due to poor efficacy it is currently only usable in combination with etesevimab. Pharmacokinetic limitations and mainly the onset of SARS-CoV-2 variants are the main reasons for this limited clinical use. In the use preventing hospitalization also has ethical limits related to the sustainability of care, especially if, considering similar effectiveness, bamlanivimab is compared with convalescent plasma.

1. Introduction

The identification of the pathophysiological pathways underlying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection \cite{1,2} was a leading step to the development of the treatments for COVID-19, including active and passive immunization strategies \cite{3–5}. While in the early pandemic old drugs with potential therapeutic benefits were tested against the infection and its complications \cite{6}, parallel investigations on targeted therapeutics started all over the world \cite{3}. In particular, the characterization of the SARS-CoV-2 portion responsible for viral entry, namely the Spike protein, represented a benchmark in COVID-19 research and drove subsequent pharmacological discovery. The Spike protein, a class I multi-domain glycoprotein exposed as a homotrimer, binds the angiotensin-converting enzyme 2 (ACE2) cellular receptor through its receptor-binding domain (RBD). The RBD upward movement allows the ACE2 receptor binding, and leads to endoproteolytic cleavage of Spike into S1 and S2 subunits. After that, virion fusion to the cell membrane and the transfer of viral genetic content into the host cell takes place \cite{1,7}. The development of neutralizing monoclonal antibodies (mAbs), having the RBD as a target, and the ability to inhibit ACE2 receptor binding, therefore preventing SARS-CoV-2 infection \cite{1,7,8} has appeared as a promising pharmacological strategy at once.

2. Discovery strategy and preclinical development

The attempt of achieving a passive immunization through the isolation of multiple neutralizing mAbs from peripheral blood mononuclear cells (PBMC) of donors both with active \cite{9,10} or resolved \cite{11–13} disease has been already made for other human pathogenic viruses such as respiratory syncytial virus (RSV), HIV, Ebola virus, Avian H5N1 influenza virus, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). MAbs have the potential of preventing and treating these emerging viruses by inhibiting entrance into host cells and subsequent virus replication \cite{9–13}. To the best of our knowledge, pavilizumab is the only mAb selected from the screening of murine convalescent blood and subsequently humanized that received a final approval for the treatment of an infectious disease, namely RSV. In the case of COVID-19, approved mAbs have been developed for the first time starting from human convalescent plasma \cite{14,15}. Notably, the experience accumulated with MERS-CoV had a central role in the development of mAbs for SARS-CoV-2 \cite{13}.
Bamlanivimab (LY-CoV555) is a mAb developed with this rationale by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. This mAb was developed starting from convalescent plasma donated from a recovered 35 years-old COVID-19 patient. About 3 weeks after the beginning of the disease signs, the PBMC were isolated. The PBMC were cryopreserved for identifying anti-Spike mAbs through two different tests, the multiplexed bead-based assay and live cell-based one. Out of 5.8 million of PBMCs screened, 4500 Abs were identified as potential candidates and 2238 single Abs were finally selected. Among these, Ab genes were sequenced and the related libraries were created. This brought to the identification of 440 high-confidence paired heavy and light chain sequences, belonging to 394 clonal families. The 4% of the identified Abs displayed cross-reactivity to both the SARS-CoV-2 and SARS-CoV Spike proteins, and 187 Abs were eligible for cloning and expression. Overall, recombinant mAbs were generated from 175 sequences cloned and they were evaluated with regard to stability, solubility, oligomerization, polydispersity, affinity, binding kinetics, binding validation, functional validation and epitope binding. Out of 24 mAbs with good properties, only 9 showed ACE2 blocking activity. When neutralization activity was tested in different in vitro experiments, Ab #169 (immunoglobulin G1, IgG1), displayed the greatest neutralization potency in the Plaque Reduction Neutralization Test (PRNT) against isolates from NextStrain clades 19A and 19B: half maximal inhibitory concentration (IC$_{50}$) was 0.049 µg/mL and 0.02 µg/mL, respectively. As a consequence, this mAb was selected for further investigations. Then, it was observed that its Fab portion was able to bind RBD Spike protein both in its up and down configuration [8]. Through surface plasmon resonance, this mAb showed an activity binding to the entire Spike protein and the recombinant RBD characterized by a $K_D$ of 0.071 nM and 2.2 nM, respectively. The crystal structure of the bamlanivimab Fab showed that it binds the RBD via the amino acid residues 351, 449–450, 455–456, 470, 472, 481–489, and 492–494 of the Spike protein. This was able to inhibit Spike protein attachment to the human ACE2 with an IC$_{50}$ value of 0.025 µg/mL. As expected for an IgG1 mAb, bamlanivimab binds to FcγRI, FcγRIIA, FcγRIIb, and FcγRIla extracellular domains and to the complement protein C1q. On the contrary, no complement-dependent cytotoxicity (CDC) activity was found for bamlanivimab [8,16,17].

Reduced neutralization activity was observed when RBD variants were used in PRNTs. In particular, PRNT showed complete loss of function against WHO variants of concern (VOC) gamma (also named P.1 by PANGOLIN or 20 J/S01Y.V3 by NextStrain) [18–20], beta (also named B.1.351 by PANGOLIN and 20 H/S01Y.V2 by NextStrain) [18,19,21], and variants of interest (VOI) zeta (also named P.2 by PANGOLIN and 20B/S.484 K by NextStrain) [22], epsilon (also named B.1.427/B.1.419 by PANGOLIN and 21 C by NextStrain) [23,24], and iota (also named B.1.526 by PANGOLIN and 21 F by NextStrain) [25]. Efficacy of bamlanivimab was preserved against VOC alpha (also named B.1.1.7 by PANGOLIN and 20I/S01Y.V1 by NextStrain) [21], but was lost in the related E484K-positive eta VOI (also named B.1.525 in PANGOLIN and 21D in NextStrain) [26]. This evidence confirms that the E484K mutation, occurring in 64 out of the 800 clades reported as of March 2021 and hence being a dramatic example of convergent evolution [27], inevitably leads to full resistance to bamlanivimab [23] as well as to many other class 2 RBD-directed mAbs [28].

With regard to the possibility of antibody-dependent enhancement (ADE) of SARS-CoV-2 infection, further investigations are needed due to both the discordance in results of in vitro models and the weak pharmacokinetic information in animal models (i.e. African green monkey). Nevertheless, there is no evidence of ADE in COVID-19 to date from any neutralizing antibody-based therapy [29]. When the ability to prevent viral load and replication was assessed in bronchoalveolar lavage fluid, throat and nasal swabs of rhesus monkeys, protection was found for the lower and upper respiratory tract following a single dose of bamlanivimab [8,16]. In particular, intravenous doses ≥2.5 mg/kg administered 24 hours before intranasal and intratracheal SARS-CoV-2 inoculation achieved the highest protection in infected rhesus monkeys, with timely effects first in lung and throat and then in the nasal setting owing to a late distribution of Abs into this environment [8].

After only 94 days, Ab #169, subsequently named LY-CoV555 and later bamlanivimab, was administrated for the first time in human subjects [8]. Etesevimab (LY-CoV-016) is the second mAb developed by AbCellera Biologics and Eli Lilly, characterized by the deletion of the effector function of the Fc portion through introduction of the LALA mutation. Its affinity to FcγRI, FcγRIIA allelic variant R167, or FcγRIIa allelic variant V176 was scarce, and no ADCC and CDC activities were shown. Etesevimab binds to a different epitope of the RBD but since this epitope overlaps that of bamlanivimab, the two mAbs compete for binding, as displayed by co-crystal structural analysis [17].

### 3. Clinical development

In the Clinicaltrials.gov database and the International Clinical Trials Registry Platform (ICTRP) of the World Health Organization (WHO), 16 studies investigating bamlanivimab
for COVID-19 were retrieved [30–45]. Out of these, 10 trials involving phases from 1 to 3 were identified [31–33,35,38–43]. These involved patients with different characteristics (both outpatients with mild to moderate COVID-19 and hospitalized patients with moderate to severe COVID-19). The major characteristics of the study protocols are summarized in Table 1.

The results of BLAZE-1 and ACTIVE-3 trials have been fully published in peer reviewed journals. The BLAZE-1 was a phase 2 randomized, double-blind, placebo-controlled trial that investigated the efficacy and safety of bamlanivimab in outpatients with mild to moderate COVID-19. This involved five different treatment arms: a) placebo (n = 156); b) single infusion of bamlanivimab 700 mg (n = 101); c) single infusion of bamlanivimab 2800 mg (n = 107); d) single infusion of bamlanivimab 7000 mg (n = 101); e) a single infusion combination of bamlanivimab 2800 mg and etesevimab, 2800 mg (n = 112), respectively [46]. The change in log viral load from baseline to day 11 was the primary efficacy outcome. Viral load was measured by nasopharyngeal swab followed by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). In particular, compared with placebo, the differences were not statistically significant in the three monotherapy bamlanivimab groups but a significant difference was shown in the combination therapy group (−0.57; 95% Confidence Interval, CI, −1.00 to −0.14; p = 0.01). Several secondary outcomes were evaluated, three evaluating viral load and five assessing improvements in signs and symptoms. Statistically significant differences were observed in changes from baseline to day 29 and 11, respectively. In particular, compared with placebo, the change from baseline to day 29 in viral load area under the curve (AUC) was significant in the bamlanivimab 2800 mg group (difference = −9.50 [95% CI, −16.32 to −2.68]; p = 0.006) and in the combination therapy group (difference = −17.91 [95% CI, −25.25 to −10.58]; p < 0.001, respectively). Improvements in mean symptom score from baseline to day 11 were statistically significant in bamlanivimab 700 mg group (mean difference, −0.78 [95% CI, −1.37 to −0.20]; p = 0.009) and in combination therapy group (mean difference, −0.60 [95% CI, −1.18 to −0.03]; p = 0.04) compared with placebo.

Symptoms improvement at day 11 was observed for bamlanivimab 700 mg and 7000 mg monotherapy, respectively (difference, 16.0% [95% CI, 3.6% to 28.4%]; p = 0.02; difference, 15.0% [95% CI, 2.6% to 27.4%]; p = 0.02) compared with placebo. However, symptom resolution at day 11 was statistically significant only for the monotherapy bamlanivimab 700 mg group (difference from baseline, 13.7% [95% CI, 1.2% to 26.1%]; p = 0.04). When COVID-19-related hospitalization or emergency department visits were analyzed, only the combination group showed a statistically significant difference compared with placebo at day 29 [difference = 4.9% (95% CI, −8.9% to −0.8%; p = 0.049)]. The most frequently reported adverse drug reactions (ADRs) were: nausea (3.0% for the 700 mg group, 3.7% for the 2800 mg group, 5.0% for the 7000 mg group, 3.6% for the combination therapy group, and 3.8% for the placebo), diarrhea (1.0% for the 700 mg group, 1.9% for the 2800 mg group, 5.9% for the 7000 mg group, 0.9% for the combination therapy group, and 4.5% for the placebo) and immediate hypersensitivity reactions infusion related. In particular, the last ADR occurred in six patients in the bamlanivimab monotherapy groups, two patients in the bamlanivimab and etesevimab group and one patient in the placebo group.

To understand the possible neutralizing role of mAbs and other antiviral interventions in hospitalized patients with COVID-19, the US National Institutes of Health established the ACTIV-3/TICO (Therapeutics for inpatients with COVID-19) platform [47]. The ACTIV-3 study, comparing bamlanivimab to placebo in hospitalized patients, was the first study developed within this platform. In this study, hospitalized patients with COVID-19 were randomized in a 1:1 ratio to receive bamlanivimab or placebo. All patients received all expected supportive care, including remdesivir and, when indicated, supplemental oxygen and glucocorticoids. The interventions not allowed were those that may have provided exogenous antibodies for SARS-CoV-2, such as convalescent plasma or hyperimmune serum. Hospitalized adult patients with documented SARS-CoV-2 infection and a duration of symptoms attributable to COVID-19 lasting 12 days or less were enrolled. Patients who had received intravenous immunoglobulin, convalescent plasma from patients cured of COVID-19, or another mAb against SARS-CoV-2 were excluded from the study. Patients with organ failure or certain extra pulmonary complications were excluded. Bamlanivimab (at a dose of 7000 mg) or placebo was administered as a single intravenous infusion over 1 hour. The primary TICO protocol establishes an overall primary outcome (sustained recovery, defined as hospital discharge and out-of-hospital stay for at least 14 days, until day 90), and two outcomes on an ordinal scale measured at day 5 for futility assessment. The outcomes assessed at day 5 are termed pulmonary and pulmonary-plus outcome. The pulmonary outcome is based largely on oxygen requirements, ranging from the ability to perform all normal daily activities to death. The pulmonary-plus outcome captures the range of organ dysfunction that may be associated with COVID-19 progression, such as respiratory dysfunction and coagulation-related complications. The choice of day 5 as the primary day for evaluation was based on an assessment of ACTT-1 [48] data, which showed that remdesivir was associated with a better outcome than placebo at day 5 on an ordinal scale similar to that used in this study. On 26 October 2020, the Data and Safety Monitoring Committee recommended that enrollment be discontinued for futility after 314 patients (163 in the bamlanivimab group and 151 in the placebo group) had undergone randomization and infusion. The median interval from symptom onset was 7 days. At day 5, a total of 81 patients (50%) in the bamlanivimab group and 81 (54%) in the placebo group were in one of the two most favorable pulmonary outcome categories (Odds Ratio 0.85, 95% CI, 0.56–1.29; p = 0.45). The proportion of patients with a primary safety outcome (defined as death, serious adverse events (AEs), or clinical grade 3 or 4 AEs through day 5) was similar in the bamlanivimab group and the placebo group (19% and 14%, respectively; Odds Ratio, 1.56; 95% CI, 0.78 to 3.10; p = 0.20). The Rate Ratio for sustained recovery was 1.06 (95% CI, 0.77 to 1.47). These data indicate that patients hospitalized with COVID-19 who received a single infusion of bamlanivimab (at a dose of 7000 mg) did not have better clinical outcomes at day 5 than those who received placebo [47].
Table 1. Phase I–III clinical trials recorded in Clinicaltrials.gov database and International Clinical Trials Registry Platform (ICTRP) of the World Health Organization (WHO) for bamlanivimab up to July 7<sup>th</sup> 2021.

| Clinicaltrials.gov identifier | Study design and type of control | Date, start – end | Efficacy outcome measures | Enrolled participants | Population | Treatment groups (dosage, route) |
|-------------------------------|----------------------------------|-------------------|---------------------------|----------------------|------------|----------------------------------|
| NCT04701658                  | Phase 2 – interventional study   | January 2021 – June 2021 | Experience of COVID-19-related hospitalization or death | With mild to moderate COVID-19; not hospitalized; 12 years and older | 3000 | Experimental: Bamlanivimab (IV) Control: standard of care |
| NCT04537910/ J2X-MC-PYAG [31] | Phase 1 – randomized, placebo-controlled | September 2020 – December 2020 | PK | From 18 years to 60 years; healthy | 25 | Experimental: Bamlanivimab (700 mg, sc) No Intervention: standard of care (700 mg, sc) |
| NCT04411628/ J2W-MC-PYAA [44] | Phase 1 – randomized, placebo-controlled, double-blind | May 2020 – August 2020 | Serious Adverse Event(s); PK | Hospitalized with COVID-19 moderate or severe | 24 | Experimental: LY3819253 Bamlanivimab (700 mg, 2800 mg, 7000 mg, IV) Comparator: Placebo |
| NCT04634409/ J2X-MC-PYAH [45] | Phase 2, placebo-controlled, double-blind, randomized, single dose trial | October 2020 – April 2021 | SARS-CoV-2 Viral Load Greater than 5.27 | Ambulatory adults (18–64 years) with mild to moderate COVID-19 | 500 | Bamlanivimab (700 mg) Bamlanivimab+Etesevimab Bamlanivimab+ Etesevimab (700 mg+1400 mg) Bamlanivimab+ Etesevimab (2800 mg+2800 mg) Placebo |
| NCT04497987/ J2X-MC-PYAD [32] | Phase 3, randomized, double-blind, placebo controlled study | August 2020 – June 2021 | COVID-19 within 21 days of detection | Residents and staff of skilled nursing or assisted living facilities; prevention and treatment cohorts (from 18 years) | ≤5000 (maximum sample size) Part 1 will randomize up to 1700 participants | Placebo |
| NCT04427501/ J2W-MC-PYAB (BLAZE-1) [33] | Phase 2, randomized, double-blind, placebo controlled trial | November 2019 – May 2021 | (1) COVID-related hospitalization or death from any cause (2) Change from Baseline to day 11 in SARS-CoV-2 viral load (3) SARS-CoV-2 viral load greater than a pre-specified threshold | Mild to moderate COVID-19; participants in arms 7 & 8 have at least 1 risk factor for developing severe COVID-19 (from 12 years) | 1060 | Bamlanivimab (700 mg) Bamlanivimab (2800 mg) Bamlanivimab (7000 mg) Bamlanivimab+ Etesevimab (2800 mg+2800 mg) Placebo |

(Continued)
| Clinicaltrials.gov identifier | Study design and type of control | Date, start – end | Efficacy outcome measures | Enrolled participants | Population | Treatment groups (dosage, route) |
|------------------------------|----------------------------------|-------------------|--------------------------|-----------------------|------------|----------------------------------|
| NCT04518410/ACTIV-2 [34]    | Phase 2/3, randomized, blinded, controlled, platform trial | August 2020 – December 2021 | (1) Duration of COVID-19 symptoms (2) Post-treatment presence of SARS-CoV-2 RNA at Day 3 (3) Post-treatment presence of SARS-CoV-2 RNA at Day 7 (4) Post-treatment presence of SARS-CoV-2 RNA at Day 14 (5) Post-treatment presence of SARS-CoV-2 RNA at Day 21 (6) Post-treatment presence of SARS-CoV-2 RNA at Day 28 (7) Cumulative incidence of death from any cause or hospitalization (1) Incidence of new AE ≥ Grade 3 (2) Proportion of participants with new AE ≥ Grade 3 | Ambulatory patients with mild to moderate COVID-19 (from 18 years) | N = 1000 per arm for phase 3, inclusive of the patients enrolled in the phase 2 portion of the trial | Bamlanivimab (7000 mg initially, dose then changed to 700 mg) Placebo |
| NCT04501978/ACTIV-3 [35]    | Phase 3, randomized, blinded, controlled platform study with two stages | August 2020 – July 2022 | (1) Pulmonary ordinal outcome (disease severity stratum 1) (2) Pulmonary ordinal outcome (disease severity stratum 1) (3) Time from randomization to sustained recovery | Patients hospitalized for COVID-19 (from 18 years) | 1000 Stage 1, N = 150 participants inpatient adults with COVID-19 symptoms, without organ failure Stage 2, N = 500 participants (including those from Stage 1) | Bamlanivimab (7000 mg) Placebo |
| NCT04790240 [38]            | The trial (phase 1/2) uses medicinal herbs to direct T cells to engulf the COVID-19 virus and protect the organs well | February 2021 – March 2023 | (1) Recovering damaged organ (2) Preventing inflammation (3) Inhibiting inflammation if hospitalization occurred after monoclonal antibody administration | Patients with marks positive COVID-19 diagnosed in the past 1–20 days during the registration | | Treatment group: Medications (remdesivir, colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab, Imedevimab) and medical herbs Control group: remdesivir, colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab, Imedevimab |
| NCT04840459 [39]            | Use of monoclonal antibodies for the treatment of mild to moderate COVID-19 in non-hospitalized setting (phase 2) | November 2020 – December 2021 | (1) Rate of recovery after monoclonal antibody therapy (2) Determine if hospitalization occurred after monoclonal antibody administration | Patients from 12 years with positive results of direct SARS-CoV-2 viral testing at high risk for progression to severe COVID-19 and/or hospitalization | 1000 Bamlanivimab (Single IV infusion 700 mg) Casirivimab (10 mL) +Imedevimab (10 mL) |

AE: Adverse events; IV: intravenous; N: number; PK: Pharmacokinetic; sc: subcutaneous
A US randomized double blind phase III trial was conducted on 966 resident and staff of skilled nursing and assisted living facilities with at least one index case, enrolled between August and November 2020, and followed up to January 2021. This study showed that bamlanivimab significantly reduced the incidence of COVID-19 in the prevention population compared with placebo (8.5% vs 15.2%; odds ratio, 0.43 [95% CI, 0.28–0.68]; P < .001; absolute risk difference, −6.6 [95% CI, −10.7 to −2.6] percentage points). No deaths related to COVID-19 were reported in the bamlanivimab vs five in the placebo group [49].

On November 9th, 2020 bamlanivimab obtained its first emergency use authorization (EUA) by U.S. Food and Drug Administration (FDA), both as monotherapy or in combination with etesevimab [50].

In Europe, the two neutralizing mAbs are currently under rolling review by the European Medicine Agency (EMA) [51].

4. Post-launch

The FDA has issued the EUA for the use of the unapproved mAb bamlanivimab for the treatment of mild to moderate COVID-19 in adult and pediatric patients (>12 years old) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to hospitalization and/or severe COVID-19. Bamlanivimab, is still under investigation, and collecting post-launch data is essential [50]. EMA’s human medicines committee (CHMP) has started a rolling review on data collected for bamlanivimab used alone or in combination with etesevimab [51]. The Agency is reviewing available data on the use of bamlanivimab to treat patients with COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19.

To date, in the Clinicaltrials.gov database and the ICTRP of the WHO there are three phase 4 clinical trials [34,36,44], one expanded access program [30] and two observational studies [37,45] evaluating effectiveness and safety of bamlanivimab (Table 2). All of these studies started between January and March 2021 and, with the possible exception of the extended program for which little information is available, no results are available yet.

Real-world data about the use of bamlanivimab after EUA are scarce [52–54]. The study by Webb BJ et al. [52] described real-world effectiveness and tolerability of monoclonal antibodies against SARS-CoV-2 for ambulatory patients with early COVID-19 at high risk of hospitalization. The study was conducted in infusion centers and urgent care clinics in the United States using target trial emulation and casual inference methodology. Patients were included in pre- (July 1–27 November 2020) and post- (28 November 2020–28 January 2021) mAbs implementation groups. Among the included patients, 594 high-risk early-symptomatic adults with positive COVID-19 test receiving the mAbs (479 and 115 were treated with bamlanivimab and casirivimab/imdevimab, respectively) were compared to 5536 controls through inverse probability of treatment weighting analysis, and to 7404 patients of the pre-implementation cohort using propensity-weighted interrupted time series analysis. The results showed that treatment with monoclonal antibody was associated with fewer subsequent hospitalization and emergency department (ED) visits (odds ratio 0.69, 95% CI 0.60–0.79). In the period after the implementation, the probability of hospitalization or ED access decreased by 0.7% per day, 95% CI 0.03–0.10%, p < 0.001. Authors observed six different infusion-associated AEs for bamlanivimab: two were classified as serious (chest pain and syncope), and four not serious (oral tingling, pruritus without rush, rigors and nausea plus emesis). The study by Rainwater-Lovett et al. [53] was in line with these results. Authors evaluated 598 COVID-19 patients (270 treated with bamlanivimab and 328 untreated) and found that the risk of ED visits or hospitalization was 82% lower in patients who received the mAb than untreated subjects (95% CI 66–94%). Despite results corroborated effectiveness and safety evidence deriving from clinical trials, their reliability is limited due to observational nature of data and to the reduced sample size.

In an early matched study on 468 patients by Bariola et al., patients receiving bamlanivimab were less likely to experience hospitalization or mortality (OR 0.31) and hospitalization or emergency department visit without hospitalization (OR 0.50). The impact of bamlanivimab was more pronounced in prevention of hospitalization (among all age groups, OR 0.35) than mortality or emergency department visit without hospitalization, and most strongly associated with patients age 65 years and older (primary outcome OR 0.28) [55].

Ganesh et al. run a retrospective propensity-score matched study on 2,335 patients who received single-dose bamlanivimab infusion at Mayo Clinic facilities. Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs 3.5%; OR 0.38), 21 (1.9% vs 3.9%; OR, 0.46), and 28 (2.5% vs 3.9%; OR, 0.61). Secondary exploratory outcomes included lower intensive care unit admission rates at days 14 (0.14% vs 1%; OR, 0.12), 21 (0.25% vs 1%; OR: 0.24) and 28 (0.56% vs 1.1%; OR: 0.52), and lower all-cause mortality at days 14 (0% vs 0.33%), 21 (0.05% vs 0.4%; OR, 0.08) and 28 (0.11% vs 0.44%; OR, 0.01) [56].

Webb et al. reported that, among 13,534 high-risk adult outpatients with symptomatic, laboratory-confirmed COVID-19 within 7 days of symptom onset propensity-weighted probability of emergency department visit or hospitalization decreased by 0.7% per day under bamlanivimab [52]. In a metanalysis by Wafa et al., bamlanivimab-etesevimab decreased viral load but did not improve hospital discharge at day 28–30 [57].

Following the outbreak of COVID-19 pandemic, the FDA has developed a specific section of the FDA Adverse Event Reporting System (FAERS) Public Dashboard dedicated to drugs that have obtained the EUA [58]. The tool now ensures frequent updates of AEs reports submitted to FAERS. Despite the existence of a report does not establish a causal relationship between drug and AEs, the reporting system is useful to monitor safety issues surrounding the drug. In this pandemic context, it assumes a helpful value to supplement evidence about the new drugs under evaluation. The COVID-19 EUA FAERS Public Dashboard [58] recorded 4,323 reports of AEs for bamlanivimab monotherapy as of July 7th. In 2021, 998 and 3,682 received in 2020 and in 2021, respectively). Table 3 shows the distribution of the most reported AEs according to age groups. Among the 2,847 reported serious cases, death...
| Clinicaltrial.gov identifier | Study design and type of control | Date, start – end | Efficacy outcome measures | Enrolled participants | Population | Treatment groups (dosage, route) |
|-----------------------------|---------------------------------|------------------|--------------------------|-----------------------|-----------|---------------------------------|
| NCT04656691 [40]           | Phase 4 – open-label, pragmatic, single-dose | January 2021 – May 2021 | Hospitalization rates documenting adverse events after infusion | Participants with mild to moderate COVID-19; 65 years and older; 12 years and older (with risk factors), 65 years and older | 7500 | Bamlanivimab (700 mg IV) |
| NCT04603651 / J2X-MC-Y001 [30] | Expanded access program | / | / | / | / | / |
| NCT04796402 [36] | A pragmatic eight week phase 4 study of bamlanivimab/LY-CoV555 for emergency passive immunity against COVID-19 | March /2021- March 2021 | Any incidence of admission to hospital for >24 hours in the 28 days following first positive test for SARS-CoV-2 | High-risk for hospitalization in patients with SARS-CoV-2 | 576 | Standard of care (indicated by care provider) Bamlanivimab (700 mg/20 mL IV over at least one hour once daily) Casirivimab/imdevimab (1200 mg IV of each drug (2400 mg total) one within 10 days of COVID-19 symptom onset) Bamlanivimab+Etesevimab (700 mg/20 mL IV of each drug one within 10 days of COVID-19 symptom onset) Casirivimab/imdevimab bamlanivimab/etesevimab Other treatments authorized for emergency use Bamlanivimab (Single IV infusion 700 mg) Standard of care |
| NCT04790786 [37] | A pragmatic evaluation of monoclonal antibody treatments in participants with covid-19 illness (Observational study) | March 2021- December 2022 | Days alive and free from hospitalization | Patients that are both living and not in the hospital will meet criteria to be counted in this outcome | 5000 | Bamlanivimab (700 mg IV one within 10 days of COVID-19 symptom onset) Casirivimab/imdevimab (1200 mg IV of each drug (2400 mg total) one within 10 days of COVID-19 symptom onset) Bamlanivimab+Etesevimab (700 mg/20 mL IV of each drug one within 10 days of COVID-19 symptom onset) Casirivimab/imdevimab bamlanivimab/etesevimab Other treatments authorized for emergency use Bamlanivimab (Single IV infusion 700 mg) Standard of care |
| NCT04885452 [43] | Prospective, multicentric, non comparative study aiming to evaluate the clinical and virological evolution of high-risk patients infected with SARS-CoV-2 (Observational study) | May 2021 – July 2022 | Percentage of patients hospitalized (if the patient was outpatient) or whose hospitalization was extended for complications from COVID-19 within 1 month of symptoms onset. | Patients infected with SARS-CoV-2 | 2000 | Casirivimab/imdevimab bamlanivimab/etesevimab Bamlanivimab Other treatments authorized for emergency use Bamlanivimab (Single IV infusion 700 mg) Standard of care |
| NCT04748588 [42] | Randomized, open-label, controlled clinical trial: standard-of-care (control) vs bamlanivimab (phase 4) | February 2021 – January 2023 | (1) Proportion of participants requiring mechanical ventilation or not surviving to hospital discharge (2) in-hospital death (3) Need for mechanical ventilation (4) Need for new intensive care admission (5) Need for new oxygen administration | Adults with laboratory-confirmed SARS-CoV-2 infection nosocomially acquired | 648 | Casirivimab/imdevimab bamlanivimab/etesevimab Bamlanivimab (Single IV infusion 700 mg) Standard of care |

IV: intravenous;
Table 3. Distribution of the most reported suspected adverse drug reactions for bamlanivimab monotherapy in the FDA Adverse Event Reporting System according to age groups up to July 7th, 2021.

| System organ class Unknown | Reactions                                      | Age groups Cases (n) | 0– 1 m 2 m-2 y 12–17y 18–6465–85y >85y |
|---------------------------|------------------------------------------------|----------------------|--------------------------------------|
| General disorders and administration site conditions | Pirexia, chills, fatigue | 1,878 - 2 8 599 814 135 320 | |
| Respiratory, thoracic and mediastinal disorders | Disnea, cough, hypoxia | 1,470 1 - 11 549 680 97 132 | |
| Nervous system disorders Investigations | Headache, dizziness, tremor | 992 1 1 3 359 433 64 131 | |
| Gastrointestinal disorders | Nausea, diarrhea, vomiting | 918 1 3 3 307 439 91 74 | |
| Infections and infestations | Pneumonia, COVID-19 | 823 - - - 264 378 60 121 | |
| Injury, poisoning and procedural complications | Infusion related reaction, intentional product use issue | 673 - 1 11 287 264 44 66 | |
| Skin and subcutaneous tissue disorders | Rash, hyperidrosis, pruritus | 482 1 1 3 230 161 14 72 | |
| Cardiac disorders | Tachycardia, atrial fibrillation | 409 - - 2 131 209 43 24 | |
| Vascular disorders | Hypotension, hypertension, flushing | 368 1 - 4 163 147 21 32 | |
| Psychiatric disorders | Confusional state, mental status changes | 339 - - 1 86 175 41 36 | |

Y: years; m:months; n: number

cases were 264 and about 60% were aged between 66 and 85 years old with no gender differences. Death events were usually described in a clinical picture including cardiovascular, cardiac, and respiratory complications. About 20% of reported cases of death had information on concomitant treatments, which were likely attributable to therapies for chronic diseases or for COVID-19 (e.g. remdesivir or corticosteroids). Several important details such as time elapsed between bamlanivimab administration and events, drug dosage, or patients’ clinical picture were not available. Of note, these characteristics are essential to establish a causal relationship between bamlanivimab and any suspected AEs reported in the FAERS. Some reported AEs to bamlanivimab suggest that its post-marketing safety profile could be partially in line with that observed in the BLAZE-1 study, that reported nausea, diarrhea, dizziness, headache, pruritus, with vomiting as the most commonly reported (2–4% of subjects) AEs [46,59].

In March 2021, the FDA updated the ‘Antiviral Resistance’ section of the Fact Sheet for Healthcare Providers for the bamlanivimab by adding information of efficacy against SARS-CoV-2 variants harboring RBD mutations [60]. A sustained increase in SARS-CoV-2 variants has been demonstrated, and different mutations of RBD are arising, making the virus able to escape mAbs targeting the RBD, including bamlanivimab [23]. Due to the unknown clinical impact following the current spread of the virus variants, the U.S. government halted the administration of bamlanivimab alone, allowing provider sites to order the combination bamlanivimab/etesevimab alone to combine with the residual stock of bamlanivimab [61]. The combination of bamlanivimab and etesevimab received the EUA for the same disease condition described for the use of bamlanivimab alone in February 2021 [60,62]. Therapy with both bamlanivimab and etesevimab is expected to prevent treatment failure and/or accelerated viral evolution [60]. According to this scenario, on April 16th, 2021, the FDA decided for the revocation of the EUA for bamlanivimab as monotherapy, stating that the benefits no longer outweigh the potential risks [63]. The EUA remained for the combination with etesevimab. Of note, bamlanivimab is being investigated in combination with VIR-7831 in patients with early manifestation of COVID-19 in the phase 2 BLAZE-4 trial [39]. The available results showed that the co-administration of bamlanivimab and VIR-7831 [3] demonstrated a 70% relative reduction (p < 0.001) in persistently high viral load on day 7 compared to placebo, reaching the primary endpoint. This combination will be further investigated, especially for potential protection against known variants of SARS-CoV-2 [64]. The last update of National Institute of Health (NIH) guidelines on July 8th, 2021 recommended against the use of the combination bamlanivimab-etezimab in patients with mild to moderate COVID-19 who are at risk of clinical progression due to an increase in the prevalence of potentially resistant variants [65]. Previously, this mAb cocktail approach was used to develop the combination casirivimab/indetimab (REGN-COV), which obtained EUA by FDA in November 2020 for the same indications authorized for bamlanivimab/etesevimab. REGN-COV is made up of two mAbs binding different non-overlapping epitopes of spike RBD of SARS-CoV-2. Currently, both with REGN-COV and bamlanivimab/etesevimab are expected to remain available for emergency use to face therapeutic concerns due to the potential for further viral variants [63]. Similar approaches are represented by the long-acting mAb cocktail AZD7442 (including AZD8895 and AZD1061) [66,67], and the combinations C135 plus C144 [68], and VIR-7831 associated with VIR-7832 [69].

Further studies are needed, including comparative ones, to confirm the effectiveness and the safety profile.

5. Conclusion

The development of bamlanivimab was apparently based on a robust rationale. This mAb, selected starting from convalescent plasma, has demonstrated in vitro and in vivo pharmacodynamic and pharmacokinetic characteristics that have pushed it toward clinical trials. However, in the latter phase, the antibody showed some benefits in non-critically-ill COVID-19 patients, and no benefit in those hospitalized with more severe conditions. Nevertheless, FDA authorized this drug for emergency use in patients with mild to moderate COVID-19,
both for monotherapy and combined use with another mAb, etesevimab. In Europe, EMA has initiated the rolling review. The good safety profile of the drug was confirmed in the post-authorization period. However, the onset of resistance related to the spread of SARS-CoV-2 variants with the risk of therapeutic failure led to the FDA’s decision to suspend the EUA for monotherapy, leaving it only for the combination with etesevimab. Clinical trials still ongoing will determine the future of this drug in COVID-19 therapy.

6. Expert opinion

Since the early phase of the pandemic, the two major and more urgent medical needs for health-care systems were an effective treatment for critically ill patients and a treatment that could prevent COVID-19-related hospitalization. The development of bamlanivimab and other mAbs against SARS-CoV-2 was driven by both these needs. Although the rationale was apparently robust and the procedures that led to the selection of the antibody definitely appropriate, the antibody failed in part to meet expectations.

From a clinical perspective, the expected effectiveness of bamlanivimab in hospitalized and intensive care unit patients was not met, while some benefits were observed in patients with mild to moderate COVID-19. The authorization in emergency use for these latter subjects has created the problem of defining which patients could be suitable candidates for these treatments due to the higher risk of experiencing complications requiring hospitalization. Even if we would be able to identify them, the number of patients we need to treat to achieve a mitigation of the pressure on hospitals is likely too high to preserve the economic sustainability of health-care systems in many Countries. Furthermore, convalescent plasma can provide largely similar benefits with far lower costs [70].

There are at least two main reasons explaining why bamlanivimab failed in the goal of significantly reducing the hospital pressure.

First, the emergence and expansion of E484K-carrying SARS-CoV-2 variants resistant to bamlanivimab had been at least partially underestimated. This is probably because a better containment of the epidemic was envisaged with the social distancing measures adopted in many Countries. Nevertheless, the spread of the virus has had such characteristics as to favor the rapid onset of numerous local variants. These have been allowed to leave their borders, due to political decisions taken in the interest of social and economic stability in all countries. While convalescent plasma, hyperimmune serum and vaccine-elicited antibodies are by nature polyclonal and hence less prone to immune escape, mAbs target single epitopes, which could easily mutate under selective pressure. The strategy of antibody cocktails could represent a temporary solution (cocktails cannot escape resistance for long time if occurrence of variants is too frequent), although their economic sustainability should be carefully considered: resistance to the bamlanivimab- etesevimab cocktail due to Q493R mutation has indeed already been reported, although fitness of such strain remains unconfirmed [71]. Additionally, mAb development takes time and is slow to readapt to variants of concern, while new convalescent plasma collections can be readily restarted soon after the appearance of new variants. Secondly, if one of the purpose of developing bamlanivimab was the treatment of critically ill patients, the rationale was probably unreliable. Indeed, these patients are hospitalized because they are hypoxic due to lung inflammation. Although we can expect some benefits from blocking the infection in the lungs with bamlanivimab, it was improbable that neutralizing mAbs could be able to reverse the inflammatory process. Furthermore, in the hypothesis that the infection could have been countered in the lungs, it is reasonable to expect that the neutralizing concentrations quickly reach these tissues. To the best of our knowledge, there are no pharmacokinetic studies that can confirm that the antibody concentration in these tissues is comparable with those showing efficacy in in vitro pharmacodynamic models, or that the expected concentration in the lungs is achieved timely to improve the clinical picture. In particular, bamlanivimab is an IgG1, and these immunoglobulins cannot be secreted to mucosal tissue like IgA and IgM. It has been demonstrated that systemically administered IgG levels in bronchoalveolar lavage (BAL) can be approximately 1,000 times lower than levels of IgG in serum [72]. Furthermore, the injury of the respiratory tissue by inflammatory processes probably determines a further limitation to bioavailability. To the best of our knowledge, results of published pre-clinical test conducted in primate models showed that this mAb can reduce viral load in the respiratory mucosa when administered before viral intranasal and intratracheal inoculation. This means that the mAb could be effective when the virus is in the plasmatic phase of the infection. Unfortunately, the time window in which the viral infection is in this phase is likely narrow, and consequently, even the choice of the appropriate timing for administration of the mAb could be complicated. This hypothesis is in line with the efficacy observed in subject with mild to moderate symptoms in the early phases of the infection. It is reasonable that in a situation in which urgency in drug development had not been an essential requirement, more animal tests would have been conducted, and possible hypothetical bioavailability problems would have been verified.

In evaluating the history of the development of bamlanivimab, it is important to remember that we are facing the uncharted terrain of the first pandemic of the modern era in which, for the first time in history, global-scale immunization is being attempted. In relation to the extraordinary and emergency circumstances in which the antibody was developed, it was certainly possible that something went wrong. Unfortunately, if our hypotheses about the reason for the current limited use of bamlanivimab are correct, they likely apply to different anti-SARS-CoV-2 mAbs. Nevertheless, the experience acquired with the use of bamlanivimab was worthy for optimizing future approach to viral infections. It is possible that the strategy of developing neutralizing antiviral mAbs, will be more successful with other types of infections, especially those where the contagion is less rapid and the onset of variants less frequent. Also, special categories of patients such those that
cannot be immunized with active strategies due to efficacy (e.g. immunosuppressed patients) or safety issues (e.g., hypersensitivity) could have a great benefit from neutralizing mAbs.

**Funding**

This manuscript was not funded.

**Declaration of interest**

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

**Reviewer disclosures**

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

**ORCID**

Giulia Valdisera [http://orcid.org/0000-0003-1616-8644](http://orcid.org/0000-0003-1616-8644)  
Emiliano Cappello [http://orcid.org/0000-0003-0386-3816](http://orcid.org/0000-0003-0386-3816)

**References**

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

1. Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281–292.e6.  
•• This study describing the physiopathologic pathway of SARS-CoV-2 highlights the central role of the spike glycoprotein in Covid-19 infection.

2. Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019;105:93–116. Academic Press Inc.

3. Tuccori M, Ferraro S, Convertino I, et al. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. mAbs. Internet. 2020 [cited 2021 Feb 23];12:18581419.

4. Focosi D, Anderson AO, Tang JW, et al. Convalescent plasma therapy for covid-19: state of the art [Internet]. Clin Microbiol Rev. American Society for Microbiology; 2020 [cited 2021 Feb 24]. p. 1–17. Available from: https://pubmed.ncbi.nlm.nih.gov/32792417/

5. Krammer F. SARS-CoV-2 vaccines in development [Internet]. Nature. Nat Res; 2020 [cited 2021 Mar 22]. p. 516–527. Available from. S86.

6. Convertino I, Tuccori M, Ferraro S, et al. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients [Internet]. Crit Care. BioMed Central Ltd; 2020 [cited 2021 Apr 6]. p. 331. 24.

7. Benten SR, Dji, Wrobel AG, Xu P, et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature. Internet. 2020 [cited 2021 Feb 16];588:327–330. Available from.

•• This study displays an accurate picture on how SARS-CoV-2 enters into host cells.

8. Jones BE, Brown-Augsburger PL, Corbett KS, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv Prepr Serv Biol. Internet. 2020 [cited 2021 Feb 16]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33024963

9. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. Internet. 2011 [cited 2021 Apr 22];477:466–470.

10. Lynch RM, Boritz E, Coates EE, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. Internet. 2015 [cited 2021 Apr 22];7:319ra206–319ra206.

11. Rijal P, Elias SC, Machado SR, et al. Therapeutic monoclonal antibodiess for ebola virus infection derived from vaccinated humans. Cell Rep. 2019;27:172–186.e7.

12. Thornburg NJ, Zhang H, Bangaru S, et al. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. J Clin Invest. Internet. 2016 [cited 2021 Apr 22];126:1482–1494.

13. Han HJ, Liu JW, Yu H, et al. Neutralizing monoclonal antibodies as promising therapies against middle east respiratory syndrome coronavirus infection [Internet]. Viruses. MDPI AG; 2018 [cited 2021 Apr 22]. Available from.

14. Young J. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med. 2002;96:531–535.

15. Pollack P, Groothuis JR. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. J Infect. Chemother. Elsevier. 2002;8:201–206.

16. Lilly E, Phillips C, Advisor R. Emergency Use Authorization (EUA) for bamlanivimab 700mg IV Center for Drug Evaluation and Research (CDER) Review Identifying Information Application Type (EUA or Pre-EUA) If EUA, designate whether pre-event or intra-event EUA request. EUA EUA Application [Internet]. [cited 2021 Mar 10]. Available from. https://www.fda.gov/media/144118/download

17. CHMP. Bamlanivimab and etesevimab for the treatment of COVID-19 (Eli Lilly) Art. 5 (3) - AR for publication [Internet]. 2021 [cited 2021 Apr 22]. Available from: https://www.emea.europa.eu/en/documents/referral/elililly-company-limited-antibody-combination-bamlanivimab-etesevimab-covid19-article-53-procedure-assessment-report_en.pdf

18. Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.1.7 and B.1.1.248: escape from therapeutic 1 antibodies and antibodies induced by infection and vaccination 2 3. bioRxiv. Internet. 2021 [cited 2021 Apr 26];2021.02.11.430787. Available from. . 10.1101/2021.02.11.430787

19. Liu H, Wei P, Zhang Q, et al. S01Y.V2 and S01Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro. bioRxiv Prepr Serv Biol. Internet. 2021 [cited 2021 Apr 26]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/3369479

20. Wang P, Wang M, Yu J, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. bioRxiv Prepr Serv Biol. Internet. 2021 [cited 2021 Apr 26]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33688656

21. Widera M, Wilhelm A, Hoehl S, et al. Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro. medRxiv. Internet. [cited 2021 Apr 26];2021.02.24.21252372. Available from. . 10.1101/2021.02.24.21252372

22. Widera M, Wilhelm A, Hoehl S, et al. Limited neutralization of authentic SARS-CoV-2 variants carrying E484K in vitro. J Infect Dis. 2021 Jul 5;jaib355. 10.1093/infdis/jaib355.Onlineaheadprint.

23. Starr TN, Greaney AJ, Dingens AS, et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell reports Med [Internet]. 2021 [cited 2021 Apr 26];2:100255.

24. McCallum M, Bassi J, De Marco A, et al. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv. Internet. 2021 [cited 2021 Apr 26];2021.03.31.437925. Available from. 10.1101/2021.03.31.437925

25. Zhou H, Dcosta BM, Samanovic MI, et al. B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. bioRxiv Prepr Serv Biol. 2021 Internet. [cited 2021 Apr 26]; Available from: . http://www.ncbi.nlm.nih.gov/pubmed/33791968

26. Focosi D, Tuccori M, Baj A, et al. SARS-CoV-2 variants: a synopsis of in vitro efficacy data of convalescent plasma, currently marketed vaccines, and monoclonal antibodies. Viruses. Switzerland; 2021.
59. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med [Internet]. 2021;384:229–237.

60. Monuf A. Fact sheet for health care providers Emergency Use Authorization (EUA) of bamlanivimab authorized use [Internet]. [cited 2021 Jul 15]. Available from: https://www.fda.gov/growth charts/clinical_charts.htm.

61. U.S. Department of Health and Human Services. Update on COVID-19 variants and impact on bamlanivimab distribution [Internet]. [cited 2021 Jul 15]. Available from: https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab/Pages/default.aspx.

62. Gormley A. Bamlanivimab and Etesevimab EUA Letter of Authorization February 25, 2021.

63. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab | FDA. [cited 2021 Apr 22]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab.

64. Lilly, Vir Biotechnology and GSK announce positive topline data from the phase 2 BLAZE-4 trial evaluating bamlanivimab with VIR-7831 in low-risk adults with COVID-19 | GSK [Internet]. [cited 2021 Apr 26]. Available from: https://www.gsk.com/en-gb/media/press-releases/lilly-vir-biotechnology-and-gsk-announce-positive-topline-data-from-the-phase-2-blaze-4-trial-evaluating-bamlanivimab-with-vir-7831-in-low-risk-adults-with-covid-19/

65. The COVID-19 treatment guidelines panel's statement on the emergency use authorizations of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 [Internet]. Natl. Inst. Heal. - COVID-19 Guidel. 2021 [cited 2021 Jul 22]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-anti-sars-cov-2-monoclonal-antibodies-eua/

66. AZD7442 – a potential combination therapy for the prevention and treatment of COVID-19. Internet. ClinicalTrials.gov. [cited 2021 Apr 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04507256?term=AZD7442&cond=COVID-19&draw=2&rank=4

67. Phase III double-blind, placebo-controlled study of AZD7442 for pre-exposure prophylaxis of COVID-19 in adult. Internet. ClinicalTrials.gov. [cited 2021 Apr 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04625725?term=AZD7442&cond=COVID-19&draw=2&rank=3

68. RU anti-SARS-CoV-2 (COVID-19) mAbs in healthy volunteers. Internet. ClinicalTrials.gov. [cited 2021 Apr 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04700163?term=c135%2C+Q493R&cond=COVID-19&draw=2&rank=1

69. AGILE (Early Phase Platform Trial for COVID-19) [Internet] [cited 2021 Apr 26]. Available from: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04746183?term=AGILE&cond=COVID-19&draw=2&rank=4

70. Focosi D, Franchini M. COVID-19 convalescent plasma therapy: hit fast, hit hard! Vox Sang. Internet. 2021 [cited 2021 Apr 29]; Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/vox.13091

71. Focosi D, Novazzi F, Genoni A, et al. Emergence of SARS-CoV-2 Spike Escape Mutation Q493R After Bamlanivimab/Etesevimab Treatment for COVID-19 [Internet]. Res. Sq. 2021. p. 3–6. Available from: https://www.researchsquare.com/article/rs-524959/v1

72. Borrok MJ, DiGiandomenico A, Beyaz N, et al. Enhancing IgG distribution to lung mucosal tissue improves protective effect of anti-Pseudomonas aeruginosa antibodies. JCI Insight. Internet. 2018 [cited 2021 Apr 26];3.